Ceralasertib plus immunotherapy for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests whether a drug called ceralasertib can help the immune system work better, followed by durvalumab plus nab-paclitaxel. It is for people with advanced triple-negative breast cancer whose cancer returned after earlier treatment, including chemotherapy and immune therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (age 18 or older) and be able to follow all study visits and instructions.
- Be able to swallow and keep down oral study pills (céralasertib).
- Have advanced (metastatic) triple-negative breast cancer that has returned after earlier curative treatment that included both immune therapy and chemotherapy.
- Have tumor testing showing hormone receptors ER/PgR are negative (less than 10%) and HER2 is not amplified.
- Have signs of cancer growth since the last earlier treatment, and have “measurable” disease on scans/tests.
- Have strong enough body function: good bone marrow, liver, and kidney test results within 28 days, and generally good performance status (ECOG 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) given with standard chemotherapy, compared to chemotherapy alone, for people with triple-negative breast cancer that has spread and hasn't been helped by earlier treatments. The goal is to see if adding this immunotherapy can shrink tumors or slow the cancer's growth better than chemotherapy alone.
This trial tests a new combination of an immunotherapy drug (camrelizumab) with chemotherapy (nab-paclitaxel) and an allergy medicine (levocetirizine) for people with triple negative breast cancer that has spread or come back. The goal is to see if this combination can shrink tumors and improve outcomes.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This trial tests a new immunotherapy drug (cadonilimab) combined with a chemotherapy (eribulin) against chemotherapy alone for triple-negative breast cancer that has come back or spread. If you receive the combination, the goal is to see if it helps control the cancer better or for longer.
This trial is testing a combination of three drugs—sacituzumab govitecan, nivolumab, and relatlimab—for people with metastatic triple-negative breast cancer that has progressed after at least one prior therapy. You may qualify if you have this specific type of breast cancer and have received certain prior treatments.
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
Hear when a new Triple Negative Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.